N-Acetyl Semax Amidate Reconstitution Calculator

No. It is not FDA- or EMA-approved and has no completed human registration trials; reviews of investigational peptides list Semax-class compounds among agents lacking long-term safety validation. The parent peptide Semax is a registered medicine in Russia, widely prescribed for ischemic stroke. NA Semax Amidate itself is distributed through research-peptide channels (community protocol).

Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (the ACTH(4-7) fragment plus a Pro-Gly-Pro tail). The amidate adds N-terminal acetylation and C-terminal amidation. Both modifications address enzymatic weak points: rat blood enzymes cleave Semax from the N-terminus (in-vitro), while carboxypeptidases degrade analogues at the C-terminus (in-vitro). The acetylated form resists proteolysis in biological media. N-terminal acetylation also measurably alters copper(II)/zinc(II) coordination and biological properties (in-vitro). Net effect: whether the two caps materially increase half-life or brain uptake versus unmodified Semax in vivo is unquantified (community protocol).

Intranasal is the established route for Semax-class drugs; clinical use of the parent peptide employs 0.1% nasal drops. Community protocols for the amidate use intranasal 100–600 mcg/day or subcutaneous 100–250 mcg/day (community protocol). Subcutaneous delivery gives more predictable systemic absorption; intranasal is more convenient and is the route validated in clinical Semax studies. Oral is not used because the peptide is rapidly degraded by serum peptidases.

Standard community protocols: intranasal 100–200 mcg 1–2× daily (up to 400–600 mcg/day in divided doses) or subcutaneous 100–250 mcg/day (community protocol). Rodent reference: 60 nmol/kg/day (~50 mcg/kg, i.p.) reversed stress-induced anhedonia, adrenal hypertrophy, and restored hippocampal BDNF (animal). Clinical dosing of the parent peptide uses 0.1% solution (~1 mg/mL) applied intranasally. No human dose-response data exist for the amidate; start at the low end and titrate (practitioner consensus).

Human safety data are limited to the parent peptide. A 36-patient glaucoma study using 0.1% Semax for one month reported no adverse reactions (clinical). Semax is practically devoid of hormonal ACTH activity, and the parent drug has decades of post-stroke clinical use in Russia; an early 30-patient acute-stroke trial showed accelerated neurologic recovery (clinical) [2, 6]. Pregnancy and breastfeeding: no human or teratogenicity data exist, so avoid use (practitioner consensus). Long-term safety for the amidate is unvalidated.

Onset and single-dose duration are reported in minutes to hours for cognitive effects (community-reported); sustained neurotrophic changes (BDNF-dependent) require daily dosing: animal studies used daily administration over 20 days (animal). A human study of the parent peptide demonstrated nootropic-like cognitive activity in volunteers. Typical community cycles: 2–4 weeks on, 2–4 weeks off (community protocol). Continuous long-term use lacks safety data.

Lyophilized NA Semax Amidate powder: store at −20°C to 4°C, protected from light and moisture (community protocol). The acetyl/amide modifications confer resistance to enzymatic degradation in biological media rather than thermal stability [8, 9]. Reconstituted solution (typically in bacteriostatic water or sterile saline) should be refrigerated and used within ~30 days (practitioner consensus).